Download PDF
Hamostaseologie 2023; 43(06): 411-417
DOI: 10.1055/a-2018-7014
Original Article

Factor XIII and Endothelial Dysfunction in Patients with Systemic Sclerosis

Sonja Alesci
1   Frankfurt Haemophilia Centre, Goethe University Frankfurt, Frankfurt am Main, Hessen, Germany
2   MVZ IMD GmbH Gerinnungszentrum Hochtaunus, Bad Homburg, Hessen, Germany
,
Matthias Wahle
3   Department of Rheumatology, Medical Clinic III, University Hospital Augsburg, Augsburg, Bayern, Germany
,
Andrea Himsel
4   Department of Rheumatology, GPR MVZ Rüsselsheim, Medical Clinic I, Rüsselsheim, Hessen, Germany
,
Wolfgang Miesbach
1   Frankfurt Haemophilia Centre, Goethe University Frankfurt, Frankfurt am Main, Hessen, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Systemic sclerosis (SSc, scleroderma) is a severe autoimmune connective tissue disease which affects the skin and internal organs. There has been evidence that coagulation factor XIII (FXIII) has a positive impact on clinical results in patients with SSc. In a single-center cohort study, we investigated the relationship between coagulation FXIII, endothelial dysfunction, and skin infection in SSc. Fifty-six patients could be included and were divided into two groups (with and without scleroderma). Markers of inflammation, coagulation, and endothelial dysfunction like C-reactive protein, leucocytes, fibrinogen, FVIII, VWF-Ag (von Willebrand factor antigen), D-dimers, and vascular endothelial growth factor were analyzed as well as MRSS (modified Rodnan skin scores) data were evaluated. Reduced daily activities were evaluated by the Scleroderma Health Assessment Questionnaire (SHAQ). There were no significant correlations between FXIII activity, MRSS, and SHAQ score. There were correlations between FXIII activity and Raynaud's phenomenon–related symptoms and a weak but not significant positive correlation with the level of pain. A significant correlation between VWF-Ag and lung-associated complaints (n = 56; p = 0.41, p < 0.0001) was found. Moreover, the study showed a correlation between VWF-Ag and MRSS (r [N = 48] = 0.4, p = 0.01), which means that higher VWF-Ag levels come along with more severe skin involvement. A trend toward a negative correlation between FXIII activity and VWF-Ag as marker of endothelial dysfunction was found (r [N = 56] = − 0.20, p = 0.15). In our cohort, there is no FXIII deficiency in patients with SSc. FXIII might have a role in improving cutaneous manifestations indirectly by means of a moderating influence on endothelial dysfunction. Further clinical evaluation is needed.

Keywords

factor XIII - transglutaminases - scleroderma - endothelial cells - von Willebrand factor


Publication History

Received: 19 July 2022

Accepted: 31 December 2022

Article published online:
01 May 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Cerinic MM, Valentini G, Sorano GG. et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003; 32 (05) 285-295
    CrossrefPubMedGoogle Scholar
  • 2 Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol 2015; 90 (01) 62-73
    CrossrefPubMedGoogle Scholar
  • 3 Rongioletti F, Ferreli C, Atzori L, Bottoni U, Soda G. Scleroderma with an update about clinico-pathological correlation. G Ital Dermatol Venereol 2018; 153 (02) 208-215
    PubMedGoogle Scholar
  • 4 Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med 2020; 201 (06) 650-660
    CrossrefPubMedGoogle Scholar
  • 5 Pai S, Hsu V. Are there risk factors for scleroderma-related calcinosis?. Mod Rheumatol 2018; 28 (03) 518-522
    CrossrefPubMedGoogle Scholar
  • 6 Lescoat A, Cavalin C, Ballerie A. et al. Silica exposure and scleroderma: more bridges and collaboration between disciplines are needed. Am J Respir Crit Care Med 2020; 201 (07) 880-882
    CrossrefPubMedGoogle Scholar
  • 7 Hirahara K, Shinbo K, Takahashi M, Matsuishi T. Suppressive effect of human blood coagulation factor XIII on the vascular permeability induced by anti-guinea pig endothelial cell antiserum in guinea pigs. Thromb Res 1993; 71 (02) 139-148
    CrossrefPubMedGoogle Scholar
  • 8 Noll T, Wozniak G, McCarson K. et al. Effect of factor XIII on endothelial barrier function. J Exp Med 1999; 189 (09) 1373-1382
    CrossrefPubMedGoogle Scholar
  • 9 Wozniak G, Noll T, Akintürk H, Thul J, Müller M. Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease. Ann N Y Acad Sci 2001; 936: 617-620
    CrossrefPubMedGoogle Scholar
  • 10 Schroth M, Meißner U, Cesnjevar R. et al. Plasmatic [corrected] factor XIII reduces severe pleural effusion in children after open-heart surgery. Pediatr Cardiol 2006; 27 (01) 56-60
    CrossrefPubMedGoogle Scholar
  • 11 Nahrendorf M, Hu K, Frantz S. et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 2006; 113 (09) 1196-1202
    CrossrefPubMedGoogle Scholar
  • 12 Streit M, Velasco P, Riccardi L. et al. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J 2000; 19 (13) 3272-3282
    CrossrefPubMedGoogle Scholar
  • 13 Dardik R, Solomon A, Loscalzo J. et al. Novel proangiogenic effect of factor XIII associated with suppression of thrombospondin 1 expression. Arterioscler Thromb Vasc Biol 2003; 23 (08) 1472-1477
    CrossrefPubMedGoogle Scholar
  • 14 Dardik R, Loscalzo J, Eskaraev R, Inbal A. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol 2005; 25 (03) 526-532
    CrossrefPubMedGoogle Scholar
  • 15 Dardik R, Krapp T, Rosenthal E, Loscalzo J, Inbal A. Effect of FXIII on monocyte and fibroblast function. Cell Physiol Biochem 2007; 19 (1-4): 113-120
    CrossrefPubMedGoogle Scholar
  • 16 Marzano AV, Federici AB, Gasparini G, Mannucci PM, Caputo R, Berti E. Coagulation factor XIII, endothelial damage and systemic sclerosis. Eur J Dermatol 2000; 10 (01) 14-17
    PubMedGoogle Scholar
  • 17 Thivolet J, Perrot H, Meunier F, Bouchet B. Therapeutic action of coagulation factor XIII in scleroderma. 20 cases. Nouv Presse Med 1975; 4 (39) 2779-2782
    PubMedGoogle Scholar
  • 18 Pilger E, Bertuch H, Ulreich A, Rainer F. Capillary permeability in connective tissue disease: influence of fibrogammin P-therapy. Thromb Haemost 1987; 58: 81
    PubMedGoogle Scholar
  • 19 Guillevin L, Chouvet B, Mery C. et al. Treatment of progressive systemic sclerosis using factor XIII. Pharmatherapeutica 1985; 4 (02) 76-80
    PubMedGoogle Scholar
  • 20 Paye M, Read D, Nusgens B, Lapière CM. Factor XIII in scleroderma: in vitro studies. Br J Dermatol 1990; 122 (03) 371-382
    CrossrefPubMedGoogle Scholar
  • 21 Delbarre F, Godeau P, Thivolet J. Factor XIII treatment for scleroderma. Lancet 1981; 2 (8239): 204
    CrossrefPubMedGoogle Scholar
  • 22 Dickneite G, Herwald H, Korte W, Allanore Y, Denton CP, Matucci Cerinic M. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions. Thromb Haemost 2015; 113 (04) 686-697
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Pongkulkiat P, Thinkhamrop B, Mahakkanukrauh A, Suwannaroj S, Foocharoen C. Skin model for improving the reliability of the modified Rodnan skin score for systemic sclerosis. BMC Rheumatol 2022; 6 (01) 33
    CrossrefPubMedGoogle Scholar
  • 24 Medsger Jr TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003; 21 (03) (3, Suppl 29): S42-S46
    PubMedGoogle Scholar
  • 25 Greenblatt MB, Aliprantis AO. The immune pathogenesis of scleroderma: context is everything. Curr Rheumatol Rep 2013; 15 (01) 297
    CrossrefPubMedGoogle Scholar
  • 26 Maekawa Y, Nogita T, Yamada M. Favorable effects of plasma factor XIII on lower esophageal sphincter pressure of progressive systemic sclerosis. Arch Dermatol 1987; 123 (11) 1440-1441
    CrossrefPubMedGoogle Scholar
  • 27 Jullien D, Souillet L, Faure M, Claudy A. Coagulation factor XIII in sclerodermaEur. J Dermatol 1998; 8 (04) 231-234
    PubMedGoogle Scholar
  • 28 Guillevin L, Chouvet B, Mery C, Thivolet J, Godeau P, Delbarre F. Traitement de la sclérodermie généralisée par le facteur XIII. Etude chez 25 sujets. La Revue de Médecine Interne 1982; 3 (03) 273-277
    CrossrefPubMedGoogle Scholar
  • 29 Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2006; 4 (01) 19-25
    CrossrefPubMedGoogle Scholar
  • 30 Cutolo M, Herrick AL, Distler O. et al; CAP Study Investigators. Nailfold Videocapillaroscopic features and other clinical risk factors for digital ulcers in systemic sclerosis: a multicenter, prospective cohort study. Arthritis Rheumatol 2016; 68 (10) 2527-2539
    CrossrefPubMedGoogle Scholar
  • 31 NCT02551042. Sclero XIII since. 2015
    PubMedGoogle Scholar